Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Overview

The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.

Interventions

• Biological TBI-1301
  Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.
• Drug Cyclophosphamide
  Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
• Drug Fludarabine
  Fludarabine (30mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

Primary outcome measures

• Objective response rate [Time frame: 52 weeks]

Eligibility criteria

Inclusion criteria

• ≥ 18 years of age
• Histologically confirmed synovial sarcoma
• Surgically unresectable tumor
• Progressing or recurrent synovial sarcoma which has been treated with 1-4 regimens of systemic chemotherapies including anthracycline
• HLA-A\*02:01 or HLA-A\*02:06 positive
• Tumor that express NY-ESO-1 by immunohistochemistry
• Measurable lesions that are evaluable by the RECIST ver1.1
• ECOG Performance Status of 0, 1 or 2
• No treatment such as chemotherapy and be expected to recover fully from the previous treatment at the time of the lymphocytes collection for manufacturing
• Life expectancy ≥ 16 weeks after consent
• No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc) and meet the following lab value criteria; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(GOT), ALT(GPT) < 3.0 x ULN; Creatinine < 1.5 x ULN; 2,500/μL < WBC ≤ULN; Hemoglobin ≥ 8.0g/dL; Platelets ≥ 75,000/μL
• Patients must be able to understand the study contents and to give a written consent at his/her free will.

Exclusion criteria

• Patients with the following conditions are excluded from the study; Unstable angina, cardiac infarction, or heart failure; Uncontrolled diabetes or hypertension; Active infection; Obvious interstitial pneumonia or lung fibrosis by chest X-ray; Active autoimmune disease requiring steroids or immunosuppressive therapy.
• Active metastatic tumor cell invasion into CNS
• Active multiple cancer
• Positive for HBs antigen or HBV-DNA observed in serum
• Positive for HCV antibody and HCV-RNA observed in serum
• Positive for antibodies against HIV or HTLV-1
• History of serious hypersensitivity reactions to bovine or murine derived substances.
• History of hypersensitivity reaction to ingredients or excipients of investigational drugs used in this study
• History of hypersensitivity reaction to antibiotics used in manufacturing for the investigational drug used in this study.
• History of treatment with cell therapy or gene therapy
• Alcohol or drug dependence that may interfere with study participation
• Pregnant females, lactating females (except when they cease and do not resume lactation) or female and male patients who cannot agree to practice the adequate birth control from the consent to 6 months after infusion of the investigational drug.
• Clinically significant systemic illness that in the judgment of the PI or sub-investigator would compromise the patient's ability to tolerate protocol therapy or significantly increase the risk of complications.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

Japan · 2 centers

• Osaka International Cancer Institute — Osaka
• Kyusyu University Hospital — Fukuoka

Identifiers

NCT: NCT07174427 · 1301-04

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗